表皮生长因子受体酪氨酸激酶抑制剂联合用药治疗非小细胞肺癌的研究进展  

Advances in epidermal growth factor receptor-tyrosine kinase inhibitor combination therapy in non-small cell lung cancer

作　　者：王乐[1,2] 李明春[1] 

机构地区：[1]中国人民解放军第401医院药剂科,山东青岛266071 [2]青岛大学药学院药理学系,山东青岛266021

出　　处：《中国药理学与毒理学杂志》2015年第4期638-642,共5页Chinese Journal of Pharmacology and Toxicology

摘　　要：以吉非替尼、厄洛替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)广泛用于非小细胞肺癌的治疗。但随着EGFR-TKI的不断应用,肿瘤细胞对药物的敏感性逐渐下降,药物作用疗效降低,耐药问题也逐渐凸显。近年来,EGFR-TKI联合用药的研究不断深入,取得了显著的成果。本文就EGFR-TKI联合化疗药物、胰岛素样生长因子1受体酪氨酸激酶抑制剂、抗血管内皮生长因子单抗、哺乳动物雷帕霉素靶蛋白抑制剂、环氧化酶2抑制剂、细胞因子诱导的杀伤细胞疗法和其他药物靶向治疗非小细胞肺癌的疗效及相关机制作简要概述,为临床治疗非小细胞肺癌提供参考。Epidermal growth factor receptor-tyrosine kinase inhibitors（ EGFR-TKI）, such as gefitinib and erlotinib, were widely used in the treatment of non-small cell lung cancer （NSCLC）. However, with the continuous application of EGFR-TKI, the sensitivity to tumor cells and the efficacy were reduced and drug resistance increased. Recently, much progress has been made in combining EGFR-TKI with other drugs. This paper summarizes the efficacy and molecular mechanism of EGFR-TKI combined with che- motherapeutic drugs, insulin-like growth factor 1 receptor TKI, antivascular endothelial growth factor monoclonal antibody, mammalian target of sirolimus（Rapamycin） inhibitor, cyclooxygenase-2 inhibitor, cytokine induced killer cell therapy and other drugs in order to facilitate clinical treatment of NSCLC.

关 键 词：表皮生长因子受体酪氨酸激酶 抑制剂 非小细胞肺癌 吉非替尼 厄洛替尼 联合用药 

分 类 号：R734.2[医药卫生—肿瘤]